Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( ChemGenex Pharmaceuticals ) Identifier:
First received: May 7, 2008
Last updated: May 9, 2014
Last verified: May 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2009
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)